Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-CTC: Trastuzumab in HER2-negative Breast Cancer with CTCs
NCT01548677Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2013
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by European Organisation for Research and Treatment of Cancer. Started Apr 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01548677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01548677.